{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:36:59Z","timestamp":1790005019132,"version":"4.0.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"2","funder":[{"DOI":"10.13039\/100007553","name":"Aids Fonds","doi-asserted-by":"publisher","award":["2015009"],"award-info":[{"award-number":["2015009"]}],"id":[{"id":"10.13039\/100007553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2,1]]},"DOI":"10.1093\/jac\/dkx396","type":"journal-article","created":{"date-parts":[[2017,10,3]],"date-time":"2017-10-03T07:08:14Z","timestamp":1507014494000},"page":"484-489","source":"Crossref","is-referenced-by-count":25,"title":["CNS penetration of ART in HIV-infected children"],"prefix":"10.1093","volume":"73","author":[{"given":"Malon","family":"Van den Hof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Blokhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette J","family":"Scherpbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinand W N M","family":"Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M C M","family":"Pistorius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeltje A","family":"Kootstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron A A","family":"Mathot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dasja","family":"Pajkrt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,11,8]]},"reference":[{"key":"key\n\t\t\t\t20180123023228_dkx396-B1","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1097\/QAD.0b013e32832dc041","article-title":"Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents","volume":"23","year":"2009","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1212\/WNL.0000000000002209","article-title":"Cerebral injury in perinatally HIV-infected children compared to matched healthy controls","volume":"86","year":"2016","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B3","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/cid\/ciu1144","article-title":"Poorer cognitive performance in perinatally HIV-infected children versus healthy socioeconomically matched controls","volume":"60","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B4","doi-asserted-by":"crossref","first-page":"e3093.","DOI":"10.1097\/MD.0000000000003093","article-title":"Neurometabolite alterations associated with cognitive performance in perinatally HIV-infected children","volume":"95","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B5","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/QAD.0000000000000766","article-title":"White matter micro-structural changes in ART-naive and ART-treated children and adolescents infected with HIV in South Africa","volume":"29","year":"2015","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/13548506.2011.648201","article-title":"Neurodevelopmental delay among HIV-infected preschool children receiving antiretroviral therapy and healthy preschool children in Soweto, South Africa","volume":"17","year":"2012","journal-title":"Psychol Health Med"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1089\/apc.2009.0314","article-title":"Poor cognitive functioning of school-aged children in Thailand with perinatally acquired HIV infection taking antiretroviral therapy","volume":"24","year":"2010","journal-title":"AIDS Patient Care STDS"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B8","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40262-015-0257-3","article-title":"Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations","volume":"54","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B9","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40262-014-0171-0","article-title":"Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system","volume":"53","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B10","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/QAI.0b013e318247ec54","article-title":"Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir","volume":"59","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B11","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/jac\/dkq434","article-title":"Efavirenz concentrations in CSF exceed IC50 for wild-type HIV","volume":"66","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B12","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1128\/AAC.02329-12","article-title":"Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration","volume":"57","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B13","first-page":"325","article-title":"Study on the concentrations of cerebrospinal fluid immunoglobulin G and albumin in children","volume":"33","year":"1992","journal-title":"Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B14","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1651-2227.1981.tb05536.x","article-title":"Concentrations of CSF proteins as a measure of blood brain barrier function and synthesis of IgG within the CNS in \u2032normal\u2032 subjects from the age of 6 months to 30 years","volume":"70","year":"1981","journal-title":"Acta Paediatr Scand"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1089\/088922203769232629","article-title":"Protein binding in antiretroviral therapies","volume":"19","year":"2003","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B16","author":"Administration US FDA"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B17","doi-asserted-by":"crossref","first-page":"1.","DOI":"10.1186\/1743-8454-3-1","article-title":"The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses","volume":"3","year":"2006","journal-title":"Cerebrospinal Fluid Res"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B18","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/jcph.612","article-title":"Cerebrospinal fluid concentrations of tenofovir and emtricitabine in the setting of HIV-1 protease inhibitor-based regimens","volume":"56","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B19","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1097\/QAD.0b013e3283489cb1","article-title":"Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage","volume":"25","year":"2011","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archneurol.2007.31","article-title":"Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system","volume":"65","year":"2008","journal-title":"Arch Neurol"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B21","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00003088-200847060-00001","article-title":"A review of the pharmacokinetics of abacavir","volume":"47","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B22","year":"2010"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B23","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1128\/AAC.49.6.2504-2506.2005","article-title":"Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid","volume":"49","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B24","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1128\/AAC.46.3.896-899.2002","article-title":"Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy","volume":"46","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B25","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(98)07333-4","article-title":"Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine","volume":"351","year":"1998","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B26","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/jac\/dkr492","article-title":"Antiretroviral drug treatment of CNS HIV-1 infection","volume":"67","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B27","volume-title":"Viread (Package Insert).","year":"2010"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B28","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/01.aids.0000171409.38490.48","article-title":"Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV","volume":"19","year":"2005","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B29","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1345\/aph.1M399","article-title":"Lopinavir cerebrospinal fluid steady-state trough concentrations in HIV-infected adults","volume":"43","year":"2009","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B30","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1128\/AAC.06311-11","article-title":"Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval","volume":"56","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B31","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1124\/dmd.112.049601","article-title":"Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid","volume":"41","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B32","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/sj.tpj.6500374","article-title":"Overview of the pharmacogenetics of HIV therapy","volume":"6","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B33","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/clpt.2008.98","article-title":"Genetic variation in drug transporters in ethnic populations","volume":"84","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/11318110-000000000-00000","article-title":"Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action","volume":"49","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B35","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1128\/AAC.48.2.437-443.2004","article-title":"Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1","volume":"48","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B36","first-page":"5938","article-title":"Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data","volume-title":"Antimicrob Agents Chemother","year":"2012"},{"key":"key\n\t\t\t\t20180123023228_dkx396-B37","author":"Administration US FDA"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/73\/2\/484\/23610213\/dkx396.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T01:49:36Z","timestamp":1570153776000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/73\/2\/484\/4604697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,8]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,11,8]]},"published-print":{"date-parts":[[2018,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkx396","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,2]]},"published":{"date-parts":[[2017,11,8]]}}}